Aspirin in Established MASLD/MASH: protocol for a systematic review and meta-analysis of effectiveness and safety
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This preregistration covers a systematic review and, where appropriate, meta-analysis of aspirin use and outcomes among adults with established metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH; legacy NAFLD/NASH terms included). The review excludes general-population prevention studies and focuses on patients with disease already present at baseline. Critical outcomes are incident HCC, major liver outcomes/decompensation, liver-related mortality, all-cause mortality, major bleeding, and longitudinal fibrosis progression/regression. Supportive outcomes include steatosis, activity/histology metrics, MACE, and other safety outcomes. Searches will be run from inception in PubMed/MEDLINE, Embase, CENTRAL, Scopus, and Web of Science without date limits. RoB 2, ROBINS-I, and GRADE will be used. Quantitative synthesis will only be undertaken when studies are sufficiently comparable within the same outcome family, estimand, and design stream.
Fields of Study & Subjects
Liver Disease Diagnosis and Treatment
Hepatocellular Carcinoma Treatment and Prognosis
Drug-Induced Hepatotoxicity and Protection
Publication details
- Publication date
- 1 January 2026
- Language
- EN
- Document type
- Preprint